Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non‐clear cell renal cell carcinoma: Real‐world data from a Japanese multicenter retrospective study-Reference-Cited by-同舟云学术

Clinical outcomes of nivolumab plus ipilimumab in patients with metastatic non‐clear cell renal cell carcinoma: Real‐world data from a Japanese multicenter retrospective study

Published:2022-12-21 Issue: Volume: Page:
ISSN:0919-8172
Container-title:International Journal of Urology
language:en
Short-container-title:Int J of Urology

Author:

Izumi Keita¹²³^ORCID,Inoue Masaharu¹³^ORCID,Washino Satoshi³⁴^ORCID,Shirotake Suguru³⁵,Kagawa Makoto³⁶,Takeshita Hideki³⁶,Miura Yuji³⁷,Hyodo Yoji²³,Oyama Masafumi⁵,Kawakami Satoru⁶,Miyagawa Tomoaki⁴,Saito Kazutaka²,Kageyama Yukio¹

Affiliation:

1. Department of Urology Saitama Cancer Center Kita‐adachi‐gun Saitama Japan

2. Department of Urology Dokkyo Medical University Saitama Medical Center Koshigaya Saitama Japan

3. Musashino Study Group Saitama Japan

4. Department of Urology Jichi Medical University Saitama Medical Center Omiya‐ku Saitama Japan

5. Department of Uro‐Oncology Saitama Medical University International Medical Center Hidaka Saitama Japan

6. Department of Urology Saitama Medical Center, Saitama Medical University Kawagoe Saitama Japan

7. Department of Medical Oncology Toranomon Hospital Minato‐ku Tokyo Japan

Publisher

Wiley

Subject

Urology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/iju.15128

Reference29 articles.

1. National Comprehensive Cancer Network.NCCN clinical practice guidelines in oncology‐kidney cancer. V.1. 2023 [Internet]. National Comprehensive Cancer Network;2022Jun [cited 2022 Jun 30]. Available from:https://www.nccn.org/professionals/physician_gls/pdf/kidney.pdf

2. Renal cell cancer histological subtype distribution differs by race and sex

3. The 2016 WHO Classification of Tumours of the Urinary System and Male Genital Organs—Part A: Renal, Penile, and Testicular Tumours

4. Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma

5. Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Changes in outcome of patients with advanced non-clear cell renal cell carcinoma from the tyrosine kinase inhibitor era to the immuno-oncology era;International Journal of Clinical Oncology;2024-08-14

2. Prognostic significance of inflammatory markers in patients with advanced renal cell carcinoma receiving nivolumab plus ipilimumab;International Journal of Clinical Oncology;2024-07-24

3. Therapeutic outcome of combination therapy using immune-checkpoint inhibitors and tyrosine kinase inhibitors for metastatic non-clear-cell renal cell carcinoma;Canadian Urological Association Journal;2024-01-30

4. Real-world outcomes of nivolumab plus ipilimumab combination therapy for advanced renal cell carcinoma in Japanese patients: data with a minimum of 3 years of follow-up;Japanese Journal of Clinical Oncology;2024-01-20

5. Cancer immunotherapy with immune checkpoint inhibitors (ICIs): potential, mechanisms of resistance, and strategies for reinvigorating T cell responsiveness when resistance is acquired;Cancer Cell International;2023-04-10